Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Oncology Study Group 8502 “QUAD shot” regimen for incurable head and neck cancer

Table 3 Univariate and multivariate analysis of the overall and progression-free survival

Variable	N	OS			PFS
		UVA	MVA		UVA
		P-value	HR (95% CI)	P-value	P-value
Age (years)
< 80	12	0.684	NA		0.265
≥ 80	22	0.684	NA		0.265
ECOG performance status
0–1	13	0.375	NA		0.847
2–3	21	0.375	NA		0.847
Tumor site
Oral cavity	19	0.627	NA		0.647
Others	15	0.627	NA		0.647
Histology
SCC	28	0.886	NA		0.482
Others	6	0.886	NA		0.482
Clinical stage
II-III	6	0.046	1	0.023	0.321
IV	28	0.046	1.922 (1.096–3.371)	0.023	0.321
Prior RT at the palliative site
Yes	7	0.910	NA		0.776
No	27	0.910	NA		0.776
Cycles of RTOG 8502
1–2	11	0.003	3.711 (1.652–8.340)	0.002	0.045
3	23	0.003	1	0.002	0.045

Abbreviations: ECOG Eastern Cooperative Oncology Group; SCC squamous cell carcinoma; RT radiotherapy; RTOG Radiation Therapy Oncology Group; OS overall survival; PFS progression-free survival; UVA univariate analysis; MVA multivariate analysis; HR hazard ratio; CI confidence interval; NA not applicable

ISSN: 1748-717X